My Medical Gateway Blog

The cost of private healthcare in the UK has reached a point where many patients are actively looking abroad for faster, more affordable treatment. But is lower cost in Europe a sign of lower quality, or something else entirely? The data across 46 treatments on the MMG platform shows a consistent and significant price gap. More importantly, it explains why European private healthcare is often both cheaper and structurally stronger.

The starting point for any serious discussion about cross-border healthcare is price. Not in isolation, but in context. The comparison between UK private healthcare and its European counterparts is often misunderstood, and sometimes deliberately so. The data tells a much clearer story.

MMG currently offers 46 treatments across eight specialties on its platform for UK patients. However, our marketing strategy in the UK is deliberately focused. Demand in Britain is overwhelmingly concentrated in orthopaedics, which accounts for 14 of those treatments. Within that segment, five procedures stand above the rest: knee replacement, hip replacement, shoulder surgery, spinal procedures and ACL repair. These sit at the very top of NHS waiting lists and represent the most acute pressure points in the system.

The pricing data across these treatments is consistent and material. A total knee replacement averages €15,304 in the UK compared to €8,723 in the EU. A total hip replacement is €14,611 in the UK versus €8,328 in Europe. ACL repair stands at €7,591 in the UK against €4,327 in the EU. Even lower complexity procedures such as knee arthroscopy follow the same pattern, at €6,519 in the UK compared to €3,716 in the EU. 

This is not limited to orthopaedics. Across general surgery, a bowel resection averages €23,987 in the UK versus €13,673 in the EU. In cardiac care, coronary artery bypass grafting is €25,719 in the UK compared to €14,660 in Europe. Across multiple specialties, the differential is typically in the range of 30 to 50 percent. 

The conclusion is straightforward. European private healthcare is materially more cost-effective than its UK equivalent. 

The more important question is why. The default assumption in the UK is that lower cost implies lower quality. That assumption does not hold. It reflects a misunderstanding of how healthcare systems are structured across Europe.

In many European countries, healthcare operates on a mixed insurance model. Public and private systems are integrated, with funding flowing through a combination of state insurance, mandatory contributions and private pay. The effect is scale. Private providers operate at significantly higher volumes, allowing for greater specialisation, more efficient use of operating capacity and lower unit costs.

By contrast, the UK private healthcare sector accounts for approximately 13 percent of total provision. It is structurally small and closely intertwined with the NHS, often sharing consultants and facilities. Capacity is constrained and pricing reflects that constraint.

European providers operate under different conditions. They are larger, more independent and more competitive. They are also, in many cases, more clinically complete. Leading European private hospitals typically possess, or have immediate access to, full emergency care capabilities. That is not consistently the case across UK private hospitals, which often rely on adjacent NHS infrastructure for acute escalation.

This matters when assessing quality. The idea that European private healthcare represents a compromise is incorrect. Standards are at least equivalent to, and often exceed, those found in the UK private sector.

MMG’s model is built around that reality. We accredit only those hospitals that meet our strict clinical, operational and governance standards (https://www.mymedicalgateway.com/mmg-hospital-standards), and that have a demonstrable record of delivering high-quality outcomes. The network is deliberately selective and focused on excellence.

It is also important to be clear about positioning. MMG is not the lowest-cost provider of treatment abroad, and we are not seeking to occupy that space. That segment of the market is already crowded, particularly in areas such as cosmetic surgery and aesthetic treatments. There will almost always be cheaper options available. That is not the objective.

MMG is focused on delivering world-class private healthcare immediately, at a price point that offers a clear and meaningful saving compared to the UK private alternative, without any compromise on quality. Our customers are not browsing for the lowest possible price. They are high-intent patients making a critically important decision to improve their quality of life, return to work and resume normal living. For them, certainty, trust and clinical quality are non-negotiable preconditions, alongside a service that must also be fairly and sustainably priced.

Patients ultimately choose based on transparency, accessibility and trust. Price is the final and decisive component of that equation. The role of MMG is to bring all of these elements together into a single, structured and seamless platform where decisions can be made quickly, clearly and with confidence.

MMG’s immediate focus on orthopaedics, and specifically on the five highest-demand procedures, reflects where the need is most acute and where the value differential is most visible. Establishing traction in this segment provides the foundation for broader customer engagement across all 46 treatments.

It is also worth noting that pricing data is not static. The figures presented are based on the most recent available information and are continuously updated as market conditions evolve. The precise numbers may shift. The structural gap between the UK and European markets will not.

For UK patients facing long waits and high private costs, the conclusion is increasingly clear. High-quality treatment in Europe is not a secondary option. It is a rational, informed choice grounded in data.

MMG exists to make that choice straightforward.